person · Reporting owner
Fahey Sandell Jacquelyn
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Voyager Therapeutics, Inc.VYGR · Entity 6271 | Chief Legal Officer | February 21, 2025 | February 24, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Voyager Therapeutics, Inc.
Report date February 21, 2025 · Filed February 24, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 123,143 |
Reported balance
After 2025-02-21 transaction · row 1
1 source rowRow 1 · 2025-02-21 · Grant · Acquired 41,500 · Balance 123,143 F1: Consists of shares of common stock issuable under an aggregate of 41,500 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 21, 2025. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.22 · Expires 2035-02-21 | Direct | 83,000 |
Reported balance
After 2025-02-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-02-21 · Grant · Acquired 83,000 · Balance 83,000 F2: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 21, 2025. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of shares of common stock issuable under an aggregate of 41,500 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 21, 2025. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.
F2: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 21, 2025. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 21, 2025 Filed Feb 24, 2025 21:18 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 83,000 | $0.00 Strike: $4.22 | $0.00 |
DisclosureSEC source: 0001104659-25-016515 · tm257355-3_4seq1.xml · derivative · entry 2 Fahey Sandell Jacquelyn · CIK 0001984647 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,000 Underlying: Common Stock · 83,000 shares Expires 2035-02-21 F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 21, 2025. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| February 21, 2025 Filed Feb 24, 2025 21:18 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantCommon Stock | 41,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-016515 · tm257355-3_4seq1.xml · nonDerivative · entry 1 Fahey Sandell Jacquelyn · CIK 0001984647 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,143 F1 · shares: Consists of shares of common stock issuable under an aggregate of 41,500 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 21, 2025. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| February 11, 2025 Filed Feb 12, 2025 21:19 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 4,358 | $4.45 | $19,393.10 |
DisclosureSEC source: 0001104659-25-012195 · tm256369-1_4seq1.xml · nonDerivative · entry 1 Fahey Sandell Jacquelyn · CIK 0001984647 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,643 F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 9, 2025. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.13 to $5.00, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| October 02, 2024 Filed Oct 3, 2024 20:43 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 5,999 | $5.82 | $34,914.18 |
DisclosureSEC source: 0001104659-24-105885 · tm2425529-1_4seq1.xml · nonDerivative · entry 1 Fahey Sandell Jacquelyn · CIK 0001984647 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,001 F1 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on October 1, 2024. The sales do not represent a discretionary trade by the reporting person. F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on October 1, 2024. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.77 to $5.88, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| February 09, 2024 Filed Feb 16, 2024 22:06 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 62,000 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0001104659-24-024998 · tm246517-5_4seq1.xml · derivative · entry 2 Fahey Sandell Jacquelyn · CIK 0001984647 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,000 Underlying: Common Stock · 62,000 shares Expires 2034-02-09 F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 9, 2024. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| February 09, 2024 Filed Feb 16, 2024 22:06 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantCommon Stock | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-024998 · tm246517-5_4seq1.xml · nonDerivative · entry 1 Fahey Sandell Jacquelyn · CIK 0001984647 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,000 F1 · shares: Consists of shares of common stock issuable under an aggregate of 31,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 9, 2024. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| October 01, 2023 Filed Oct 2, 2023 20:24 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantCommon Stock | 61,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-105910 · tm2327331-1_4seq1.xml · nonDerivative · entry 1 Fahey Sandell Jacquelyn · CIK 0001984647 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,000 F1 · shares: This equity award was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the "Company"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). F2 · shares: Consists of shares of common stock underlying a restricted stock unit ("RSU") award. Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is October 1, 2023. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting upon the one-year anniversary of such vesting commencement date and the remainder vesting in equal annual installments thereafter, subject to the Reporting Person's continued service as an employee. Read SEC document |
| July 10, 2023 Filed Jul 11, 2023 20:46 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 122,000 | $0.00 Strike: $10.18 | $0.00 |
DisclosureSEC source: 0001104659-23-080008 · tm2320946-3_4seq1.xml · derivative · entry 1 Fahey Sandell Jacquelyn · CIK 0001984647 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,000 Underlying: Common Stock · 122,000 shares Expires 2033-07-10 F1 · shares: This stock option was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the "Company"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). F2 · derivative.exercise_date: The vesting commencement date of the option is the grant date. The option vests over four years, with 1/4th of the shares of common stock underlying the option vesting upon the one-year anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service as an employee. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.